Evogene Stock to Reverse Split on Thursday, July 25th (NASDAQ:EVGN)

Evogene Ltd. (NASDAQ:EVGN) shares are set to reverse split on Thursday, July 25th. The 1-10 reverse split was announced on Tuesday, July 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 24th.

Evogene Trading Down 14.6 %

Shares of EVGN traded down $0.09 during mid-day trading on Tuesday, reaching $0.53. 967,561 shares of the stock traded hands, compared to its average volume of 138,161. Evogene has a 1 year low of $0.45 and a 1 year high of $1.12. The firm has a fifty day moving average price of $0.67 and a 200 day moving average price of $0.75. The company has a market cap of $21.85 million, a price-to-earnings ratio of -1.15 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, May 23rd. The biotechnology company reported ($0.08) EPS for the quarter. The company had revenue of $4.19 million during the quarter. Evogene had a negative return on equity of 70.96% and a negative net margin of 233.66%.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Evogene in a research report on Sunday. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets increased its holdings in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.